ArticleFrontiers in pharmacology2022

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review.

Xiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.